Genetic knockdown (KD) of either NRF2 or MTHFD1L or inhibition of the folate cycle through antifolate drug can inhibit liver cancer cell proliferation by increasing oxidative stress, altering the metabolic program, and sensitizing HCC cells to sorafenib treatment [87]. Here, NFE2L2 is linked to hepatocellular carcinoma.